ZNTL Long Call Strategy

ZNTL (Zentalis Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.

ZNTL (Zentalis Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $303.6M, a beta of 2.00 versus the broader market, a 52-week range of 1.13-6.95, average daily share volume of 1.9M, a public-listing history dating back to 2020, approximately 166 full-time employees. These structural characteristics shape how ZNTL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.00 indicates ZNTL has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on ZNTL?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current ZNTL snapshot

As of May 15, 2026, spot at $4.04, ATM IV 161.00%, IV rank 40.03%, expected move 46.16%. The long call on ZNTL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on ZNTL specifically: ZNTL IV at 161.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 46.16% (roughly $1.86 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ZNTL expiries trade a higher absolute premium for lower per-day decay. Position sizing on ZNTL should anchor to the underlying notional of $4.04 per share and to the trader's directional view on ZNTL stock.

ZNTL long call setup

The ZNTL long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ZNTL near $4.04, the first option leg uses a $4.04 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ZNTL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ZNTL shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$4.04N/A

ZNTL long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

ZNTL long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on ZNTL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on ZNTL

Long calls on ZNTL express a bullish thesis with defined risk; traders use them ahead of ZNTL catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

ZNTL thesis for this long call

The market-implied 1-standard-deviation range for ZNTL extends from approximately $2.18 on the downside to $5.90 on the upside. A ZNTL long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ZNTL IV rank near 40.03% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on ZNTL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ZNTL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ZNTL-specific events.

ZNTL long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ZNTL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ZNTL alongside the broader basket even when ZNTL-specific fundamentals are unchanged. Long-premium structures like a long call on ZNTL are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ZNTL chain quotes before placing a trade.

Frequently asked questions

What is a long call on ZNTL?
A long call on ZNTL is the long call strategy applied to ZNTL (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ZNTL stock trading near $4.04, the strikes shown on this page are snapped to the nearest listed ZNTL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ZNTL long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ZNTL long call priced from the end-of-day chain at a 30-day expiry (ATM IV 161.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ZNTL long call?
The breakeven for the ZNTL long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ZNTL market-implied 1-standard-deviation expected move is approximately 46.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on ZNTL?
Long calls on ZNTL express a bullish thesis with defined risk; traders use them ahead of ZNTL catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current ZNTL implied volatility affect this long call?
ZNTL ATM IV is at 161.00% with IV rank near 40.03%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related ZNTL analysis